search
Back to results

Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis (NERINA-SEPSIS)

Primary Purpose

Septic Shock

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Low Level Transcutaneous Vagus Nerve Stimulation
Low Level Transcutaneous Vagus Nerve Stimulation
Sponsored by
University of Oklahoma
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock focused on measuring Sepsis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Septic shock (meeting severe sepsis and having persistent systolic blood pressure <90mmHg despite adequate fluid resuscitation).

Exclusion Criteria:

  • Unilateral or bilateral vagotomy
  • History of myocardial infarction or stroke in the last 1 year
  • Recurrent vasovagal syncope
  • Sick sinus syndrome without pacemaker
  • Bifascicular heart block
  • 2nd or 3rd-degree heart block
  • Hypotension due to autonomic dysfunction
  • Pregnant women
  • Prisoners and patients with suicidal ideation

Sites / Locations

  • University of Oklahoma Health Sciences CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Active Treatment

Sham Control

Arm Description

Patients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.

Patients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.

Outcomes

Primary Outcome Measures

Change in Inflammatory Cytokine Tumor Necrosis Factor Alpha
Serum inflammatory cytokine

Secondary Outcome Measures

Change in Heart Rate Variability
Time domain and frequency domain measures of heart rate variability
Change in Sequential Organ Failure Assessment Score
Sequential Organ Failure Assessment Score calculation

Full Information

First Posted
June 5, 2019
Last Updated
October 15, 2020
Sponsor
University of Oklahoma
Collaborators
Oklahoma City VA Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03992378
Brief Title
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
Acronym
NERINA-SEPSIS
Official Title
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Recruiting
Study Start Date
November 2020 (Anticipated)
Primary Completion Date
June 2022 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oklahoma
Collaborators
Oklahoma City VA Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. It is the most expensive healthcare condition to treat in United States and has a mortality rate of nearly 30%. It is widely known that exaggerated inflammation and imbalance between sympathetic and parasympathetic arms of the autonomic nervous system (ANS) contribute to progression and adverse outcomes in sepsis. The role of unchecked inflammation and unregulated ANS as a potential treatment target is an important gap in our knowledge that should be explored. Cholinergic anti-inflammatory pathway (CAP) is an intricate network where the ANS senses inflammation by vagus nerve afferents and tries to regulate it by vagus nerve efferents to the reticuloendothelial system. The central hypothesis of this pilot clinical trial is that transcutaneous vagus nerve stimulation (TVNS) at tragus of the external ear can activate the CAP to suppress inflammation and improve autonomic imbalance as measured by inflammatory cytokine levels and heart rate variability (HRV) analysis. The investigators plan to randomize patients with septic shock into active and sham stimulation groups and study the effects of vagal stimulation on inflammatory cytokines, HRV and a clinical severity score of sepsis. Both groups will continue to receive the standard of care treatment for sepsis irrespective of group assignments. The investigators hypothesize that 4 hours of TVNS will suppress inflammatory markers and improve the balance between sympathetic and parasympathetic arms of ANS as measured by HRV, resulting in improved Sequential Organ Failure Assessment Score (SOFA). The preliminary data generated from this pilot study will lay the foundation for a larger clinical trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock
Keywords
Sepsis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial
Masking
ParticipantOutcomes Assessor
Masking Description
Double blind
Allocation
Randomized
Enrollment
34 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active Treatment
Arm Type
Experimental
Arm Description
Patients will receive a single 4-hour session of active transcutaneous vagus nerve stimulation.
Arm Title
Sham Control
Arm Type
Sham Comparator
Arm Description
Patients will receive a single 4-hour session of sham transcutaneous vagus nerve stimulation.
Intervention Type
Device
Intervention Name(s)
Low Level Transcutaneous Vagus Nerve Stimulation
Intervention Description
Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.
Intervention Type
Device
Intervention Name(s)
Low Level Transcutaneous Vagus Nerve Stimulation
Intervention Description
Stimulation of the ear lobe delivered by Parasym device.
Primary Outcome Measure Information:
Title
Change in Inflammatory Cytokine Tumor Necrosis Factor Alpha
Description
Serum inflammatory cytokine
Time Frame
Baseline to 4 hours and baseline to 24 hours post stimulation
Secondary Outcome Measure Information:
Title
Change in Heart Rate Variability
Description
Time domain and frequency domain measures of heart rate variability
Time Frame
Baseline to 4 hours post stimulation
Title
Change in Sequential Organ Failure Assessment Score
Description
Sequential Organ Failure Assessment Score calculation
Time Frame
Baseline to 24 hours post stimulation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Septic shock (meeting severe sepsis and having persistent systolic blood pressure <90mmHg despite adequate fluid resuscitation). Exclusion Criteria: Unilateral or bilateral vagotomy History of myocardial infarction or stroke in the last 1 year Recurrent vasovagal syncope Sick sinus syndrome without pacemaker Bifascicular heart block 2nd or 3rd-degree heart block Hypotension due to autonomic dysfunction Pregnant women Prisoners and patients with suicidal ideation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Houssein Youness, MD
Phone
405-271-6173
Email
Houssein-Youness@ouhsc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Zain Ul Abideen Asad, MD
Phone
405-271-5963
Email
Zain-Asad@ouhsc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Houssein Youness, MD
Organizational Affiliation
University of Oklahoma
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Zain Ul Abideen Asad, MD
Organizational Affiliation
University of Oklahoma
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Oklahoma Health Sciences Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lauren Sinko, RN
Phone
405-271-6173
Email
Lauren-A-Sinko@ouhsc.edu
First Name & Middle Initial & Last Name & Degree
Kassidy Malone, RN
Phone
4052716173
Email
Kassidy-Malone@ouhsc.edu

12. IPD Sharing Statement

Learn more about this trial

Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

We'll reach out to this number within 24 hrs